GOSS
Gossamer Bio, Inc.
- Latest sale
- $1k
- Jun 24 · No plan
- Form 4 sales
- 34
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planMar 16 2023
Sold 6,029 shares at $1.10 ($7k)
Carter Laura, Chief Scientific Officer
No 10b5-1 planSold 7.3% of holdings ($91k position)76,263 shares left1.2x usual sizeFiling
- 2 Form 4 saleNo planJun 22 +98 days
Sold 1,814 shares at $1.29 ($2k)
Aranda Richard, Chief Medical Officer
No 10b5-1 planSold 0.9% of holdings ($257k position)197,574 shares left0.4x usual sizeFiling
- 3 Form 4 saleNo planMar 18 +270 days
Sold 4,018 shares at $1.33 ($5k)
Peterson Caryn, EVP, Regulatory Affairs
No 10b5-1 planSold 7.5% of holdings ($72k position)49,833 shares leftFiling
- 4 Form 4 saleNo planMar 18 same day
Sold 4,018 shares at $1.33 ($5k)
Aranda Richard, Chief Medical Officer
No 10b5-1 planSold 2% of holdings ($270k position)198,799 shares left1.2x usual sizeFiling
- 5 Form 4 saleNo planMar 27 +9 days
Sold 23,172 shares at $1.16 ($27k)
Hasnain Faheem, President & CEO
No 10b5-1 planSold 16.2% of holdings ($166k position)120,293 shares leftFirst sale on recordFiling
- 6 Form 4 saleNo planMar 27 same day
Sold 6,430 shares at $1.16 ($7k)
Giraudo Bryan, COO/CFO
No 10b5-1 planSold 6.5% of holdings ($115k position)92,737 shares leftFirst sale on recordFiling
- 7 Form 4 saleNo planMar 27 same day
Sold 6,430 shares at $1.16 ($7k)
Christian Waage, EVP, Tech Ops and Admin
No 10b5-1 planSold 1.1% of holdings ($687k position)585,934 shares leftFirst sale on recordFiling
- 8 Form 4 saleNo planJun 24 +89 days
Sold 1,908 shares at $0.66 ($1k)
Aranda Richard, Chief Medical Officer
No 10b5-1 planSold 1% of holdings ($131k position)196,891 shares left0.4x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (34)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 24, 2024 | Aranda Richard | Chief Medical Officer | Form 4 sale | 1,908 | $1k | 1.0% | No plan | SEC |
| Mar 27, 2024 | Christian Waage | EVP, Tech Ops and Admin | Form 4 sale | 6,430 | $7k | 1.1% | No plan | SEC |
| Mar 27, 2024 | Giraudo Bryan | COO/CFO | Form 4 sale | 6,430 | $7k | 6.5% | No plan | SEC |
| Mar 27, 2024 | Hasnain Faheem | President & CEO | Form 4 sale | 23,172 | $27k | 16.2% | No plan | SEC |
| Mar 18, 2024 | Aranda Richard | Chief Medical Officer | Form 4 sale | 4,018 | $5k | 2.0% | No plan | SEC |
| Mar 18, 2024 | Peterson Caryn | EVP, Regulatory Affairs | Form 4 sale | 4,018 | $5k | 7.5% | No plan | SEC |
| Jun 22, 2023 | Aranda Richard | Chief Medical Officer | Form 4 sale | 1,814 | $2k | 0.9% | No plan | SEC |
| Mar 16, 2023 | Carter Laura | Chief Scientific Officer | Form 4 sale | 6,029 | $7k | 7.3% | No plan | SEC |
| Mar 16, 2023 | Aranda Richard | Chief Medical Officer | Form 4 sale | 7,563 | $8k | 3.7% | No plan | SEC |
| Mar 16, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Form 4 sale | 7,564 | $8k | 12.3% | No plan | SEC |
| Oct 24, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Form 4 sale | 4,757 | $57k | 7.2% | Plan not stated | SEC |
| Oct 24, 2022 | Carter Laura | Chief Scientific Officer | Form 4 sale | 4,876 | $59k | 5.6% | Plan not stated | SEC |
| Oct 24, 2022 | Aranda Richard | Chief Medical Officer | Form 4 sale | 4,757 | $57k | 2.3% | Plan not stated | SEC |
| Jul 1, 2022 | Carter Laura | Chief Scientific Officer | Form 4 sale | 8,808 | $73k | 9.9% | Unusual | SEC |
| Jun 22, 2022 | Aranda Richard | Chief Medical Officer | Form 4 sale | 1,778 | $12k | 0.8% | Plan not stated | SEC |
| May 4, 2022 | Carter Laura | Chief Scientific Officer | Form 4 sale | 1,262 | $9k | 1.4% | Plan not stated | SEC |
| Mar 23, 2022 | Christian Waage | EVP, Tech Ops and Admin | Form 4 sale | 10,722 | $96k | 1.8% | Plan not stated | SEC |
| Mar 23, 2022 | Hasnain Faheem | President & CEO | Form 4 sale | 19,035 | $170k | 11.7% | Plan not stated | SEC |
| Mar 23, 2022 | Giraudo Bryan | COO/CFO | Form 4 sale | 10,722 | $96k | 9.8% | Plan not stated | SEC |
| Mar 16, 2022 | Carter Laura | Chief Scientific Officer | Form 4 sale | 5,002 | $41k | 5.2% | Plan not stated | SEC |
| Mar 16, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Form 4 sale | 6,279 | $52k | 8.7% | Plan not stated | SEC |
| Mar 16, 2022 | Aranda Richard | Chief Medical Officer | Form 4 sale | 6,278 | $52k | 2.9% | Plan not stated | SEC |
| Oct 25, 2021 | Peterson Caryn | EVP, Regulatory Affairs | Form 4 sale | 2,377 | $29k | 3.2% | Plan not stated | SEC |
| Oct 25, 2021 | Carter Laura | Chief Scientific Officer | Form 4 sale | 2,377 | $29k | 2.4% | Plan not stated | SEC |
| Oct 25, 2021 | Aranda Richard | Chief Medical Officer | Form 4 sale | 2,377 | $29k | 1.1% | Plan not stated | SEC |
| Mar 23, 2021 | Salter-Cid Luisa | Chief Scientific Officer | Form 4 sale | 5,491 | $52k | 2.6% | Plan not stated | SEC |
| Mar 23, 2021 | Giraudo Bryan | Chief Financial Officer | Form 4 sale | 5,490 | $52k | 4.8% | Plan not stated | SEC |
| Mar 23, 2021 | Christian Waage | EVP & General Counsel | Form 4 sale | 5,490 | $52k | 0.9% | Plan not stated | SEC |
| Dec 30, 2019 | Dupont Jakob | Chief Medical Officer | Form 4 sale | 41,994 | $632k | 100.0% | Unusual | SEC |
| Sep 20, 2019 | Omega Fund V GP Manager, Ltd. | 10% owner | Form 4 sale | 183,607 | $4M | 2.7% | Plan not stated | SEC |
| Sep 18, 2019 | Omega Fund V, L.P. | 10% owner | Form 4 sale | 82,213 | $1.8M | 1.2% | Plan not stated | SEC |
| Sep 11, 2019 | Stampacchia Otello | Director, 10% owner | Form 4 sale | 112,776 | $2.4M | 1.6% | Plan not stated | SEC |
| Sep 6, 2019 | Omega Fund V GP Manager, Ltd. | 10% owner | Form 4 sale | 21,404 | $462k | 0.3% | Plan not stated | SEC |
| Aug 29, 2019 | Salter-Cid Luisa | Chief Scientific Officer | Form 4 sale | 50,000 | $994k | 28.7% | Unusual | SEC |